Novartis’ Post

At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/daK2pMbM

Acute Myeloid Leukemia (#AML) is the most common acute leukemia affecting adults, and the development of targeted therapies is helping to improve treatment options for patients across molecularly defined subsets. At Servier, we're continuing to drive advancements in AML research as part of our ongoing commitment to improving the lives of patients. Learn more about AML: https://lnkd.in/eFA3_aYi

Patients deserve strong, clinically relevant data to support the treatment decisions they make with their healthcare provider. At BeiGene, we are propelled by cutting edge science, including elevating head-to-head clinical studies and new statistical analyses of the BTK inhibitor landscape that can help to inform those decisions.    This is why I am pleased to have an article featured in Fierce Pharma where I highlight BeiGene’s latest efficacy analysis, which compares our BTK inhibitor with another in the relapsed / refractory chronic lymphocytic leukemia (#CLL) landscape. Learn more about how our MAIC analysis improves upon recently published research and why methodology matters when it comes to comparing treatments across data sets: https://bit.ly/3J0SKQw. #patientsfirst

Notable Labs announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders. Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML). “PPMP’s recently reported, 100% accurate prediction of fosciclopirox’s clinical trial outcome has allowed us to eliminate an entire 30-patient cohort from the planned volasertib program,” said Thomas A. Bock, MD, MBA, Chief Executive Officer of Notable Labs. “This further validates our PPMP-guided development strategy to target responding patients, improve patient outcomes and reduce the risk, time, and cost of drug development.”  More information at https://lnkd.in/e7UkBsBP.   #fosciclopirox #PPMP #drugdevelopment #hematology #hematologists  #bloodcancer #precisionmedicine #leukemia #AML #MDS #cancerresearch

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universitätsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. 💡 Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases. Despite development of novel treatment options and targeted therapeutics, the 5-year survival rate in adult population is quite low, indicating towards a huge unmet need in AML treatment space. The current infographic concisely highlights the key treatment options for AML and some of the emerging therapeutic stratagems. Access the full infographic here - https://lnkd.in/epixrxas #acutemyeloidleukemia #aml #CancerResearch #TreatmentOptions #EmergingTherapies #infographic #oncofocus

Inhibikase is developing IkT-001Pro to provide people suffering from chronic myelogenous leukemia (CML) with a new and improved, safer alternative to imatinib. Learn about our development of IkT-001Pro for CML here: https://bit.ly/3fMhg8O

The KOMET-001 Phase 1b study has shown encouraging clinical activity of ziftomenib, a menin inhibitor, for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. Learn about KOMET-001 Phase 2, a registration-directed trial evaluating ziftomenib, at the 65th ASH Annual Meeting and Exposition (booth #2701) or https://lnkd.in/eEHcvHDp.

The acute myeloid leukemia (AML) market is set for substantial growth, projected to rise from $2.21 billion in 2023 to $3.21 billion by 2028 at a CAGR of 7.6%. Key drivers include an aging population, advancements in targeted and immunotherapies, and enhanced diagnostic methods. Major players like Pfizer, Roche, and Novartis are leading the way with significant R&D investments and strategic partnerships. The focus on early detection, personalized medicine, and holistic patient care is shaping the future of AML treatment. Read more https://lnkd.in/g6Xw_7By #AML #HealthcareInnovation #MedicalResearch #TargetedTherapies #Immunotherapy #CancerTreatment #tbrc #thebusinessresearchcompany #marketintelligence